Lista de obras -

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

article

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

artículo científico publicado en 2016

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

artículo científico publicado en 2016

Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level

artículo científico publicado en 2011

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

artículo científico publicado en 2017

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

artículo científico publicado en 2013

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

artículo científico publicado en 2019

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

scientific article published on 04 June 2020

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

artículo científico publicado en 2016

Corrigendum to '2017 ESC/EACTS Guidelines for the management of valvular heart disease' [Eur J Cardiothorac Surg 2017;52:616-664].

artículo científico publicado en 2017

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries

artículo científico publicado en 2014

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

artículo científico publicado en 2014

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

artículo científico publicado en 2010

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis

artículo científico publicado en 2016

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis

artículo científico publicado en 2014

Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489].

artículo científico publicado en 2016

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure

scientific article published on 09 December 2019

Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction

artículo científico publicado en 2016

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

artículo científico publicado en 2018

Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The positi

artículo científico publicado en 2020

Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure

artículo científico publicado en 2019

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

artículo científico publicado en 2019

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

scientific article published on 01 December 2019

Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases

artículo científico publicado en 2017

Inter-twinned relationship between heart failure and atrial fibrillation

scientific article published on 01 June 2020

Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice

artículo científico publicado en 2014

Muscle wasting disease: a proposal for a new disease classification

artículo científico publicado en 2014

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

artículo científico publicado en 2017

Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives

artículo científico

Sarcopenia with limited mobility: an international consensus

artículo científico publicado en 2011

Site selection for heart failure clinical trials in the USA.

artículo científico publicado en 2015

Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology

artículo científico publicado en 2020

The Role of Nutraceuticals in Statin Intolerant Patients

The role of trimetazidine after acute myocardial infarction

scientific article published on 01 October 2008

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

artículo científico publicado en 2016

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

artículo científico publicado en 2018

Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku

article

Lista de obras de

2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribut

Anti-ATP synthase autoantibodies from patients with Alzheimer's disease reduce extracellular HDL level

Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology

Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology

Corrigendum to '2017 ESC/EACTS Guidelines for the management of valvular heart disease' [Eur J Cardiothorac Surg 2017;52:616-664].

Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries

Developing therapies for heart failure with preserved ejection fraction: current state and future directions

Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis

Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis

Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489].

European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure

Exploring New Endpoints for Patients With Heart Failure With Preserved Ejection Fraction

Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry

Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica

Guía ESC/EACTS 2017 sobre el tratamiento de las valvulopatías

Heart Failure Association of the European Society of Cardiology Update on Sodium Glucose Co-transporter-2 Inhibitors in Heart Failure (an update on the Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. The positi

Heart Failure Association/European Society of Cardiology position paper on frailty in patients with heart failure

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

Independent academic Data Monitoring Committees for clinical trials in cardiovascular and cardiometabolic diseases

Inter-twinned relationship between heart failure and atrial fibrillation

Mineralocorticoid receptor antagonism induces browning of white adipose tissue through impairment of autophagy and prevents adipocyte dysfunction in high-fat-diet-fed mice

Muscle wasting disease: a proposal for a new disease classification

New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment

Recognizing hospitalized heart failure as an entity and developing new therapies to improve outcomes: academics', clinicians', industry's, regulators', and payers' perspectives

Sarcopenia with limited mobility: an international consensus

Site selection for heart failure clinical trials in the USA.

Sodium glucose co-transporter-2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology

The Role of Nutraceuticals in Statin Intolerant Patients

The role of trimetazidine after acute myocardial infarction

Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency

Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology

Wytyczne ESC dotyczące diagnostyki i leczenia ostrej i przewlekłej niewydolności serca w 2016 roku